XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Operations and Basis of Presentation - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
 3 Months Ended 0 Months Ended
Sep. 30, 2014
Sep. 30, 2014
Alimera [Member]
Oct. 24, 2014
Subsequent Event [Member]
Alimera [Member]
Operations [Line Items]      
Milestone payment upon FDA approval     $ 25.0
Percentage of royalties received from sublicensee   20.00%  
Percentage of non-royalty consideration received from sublicensee   33.00%  
Cash equivalents and marketable securities 14.3    
FDA milestone Payment Upon an FDA approval of ILUVIEN   $ 25.0